MedTrace Logo

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

NCT01953211 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2019-07-26

Study results available
· View outcomes & findings →

Summary

The degree of suppression and subsequent activation of the hypothalamic-pituitary-ovarian axis during the hormone-free interval in combined oral contraceptive (COC) hormone users varies depending on the dose of ethinyl estradiol in the formulation. This variation in activation may be associated with different side effects during the hormone free interval. Progesterone (P) remained suppressed during all 6 COC regimens (\<1.8 ng/mL), which indicates continuous contraceptive efficacy during the 7-day hormone free interval of all formulations studied.

Conditions

  • Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy

Interventions

DRUG

combined oral contraceptives

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
1998-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01953211 on ClinicalTrials.gov